IgA vasculitis (IgAV) is the most common systemic vasculitis in children. Renal involvement (IgAV nephritis) is the main determinant of prognosis, yet there is no routine blood test that reliably identifies IgAV or stratifies nephritis risk. Aberrant O-glycosylation of the IgA1 hinge region has been implicated centrally in IgAV pathogenesis. The investigators developed a mass-spectrometry assay to profile IgA1 hinge O-glycoforms from a small plasma volume and to define signatures associated with disease activity and documented renal involvement.
The study was cross-sectional and included 91 children divided into three groups: 27 with acute IgAV, 26 in remission, and 38 age-matched healthy controls. Among the patients with available renal data, 24 had documented nephritis and 29 did not. IgA was affinity-purified from 5 µL of plasma per sample, followed by trypsin digestion. Hinge-region O-glycopeptides were then quantified using liquid chromatography–mass spectrometry (LC-MS). Sixty-nine distinct O-glycoforms were quantified and then normalized to a total-IgA1 tryptic peptide to allow comparisons.
Duplicate measurements demonstrated good analytical repeatability, with a median coefficient of variation (CV) of 6% across glycoforms. This suggests the assay provides reproducible quantification from the small input volume used. The study applied normalization to a total-IgA1 peptide to account for sample-to-sample IgA1 abundance differences before comparing glycoform distributions between groups.
Group differences in glycoform abundances were assessed using nonparametric tests (Mann–Whitney and Kruskal–Wallis), and multiple testing correction employed the Benjamini–Hochberg false discovery rate (FDR). Discrimination performance for individual glycoforms and panels was evaluated by receiver operating characteristic (ROC) analysis and cross-validated logistic regression models.
Children with acute IgAV exhibited broad remodeling of the IgA1 hinge glycoform profile: 35 glycoforms differed compared with controls. The pattern favored an increase in low-sialylated, agalactosylated species and a relative decrease in more complex sialylated glycoforms. Several individual glycoforms showed strong discrimination between acute IgAV and controls, with the best glycoforms reporting area under the ROC curve (AUC) values in the range of 0.93–0.95.
In children sampled in remission, the hinge-region glycoform profile had returned to levels indistinguishable from healthy controls: no glycoform differed significantly between remission subjects and controls in the analyses reported. This normalization suggests that the aberrant glycoform signature is associated with disease activity rather than representing a fixed trait in all patients.
Comparisons focusing on renal involvement revealed two distinct patterns. First, a subset of glycoforms were altered in IgAV generally and were already modified in children without nephritis. Second, a group of renal-specific glycoforms were altered only in children with documented nephritis. The renal-associated glycoforms highlighted by the authors included H2N2S1, H3N3S5, H3N4S4, and H4N4S3. These species represent candidate markers that differentiate IgAV with renal involvement from IgAV without nephritis.
Using logistic regression panels and cross-validation, the investigators derived a four-marker glycoform panel that discriminated nephritis among children with IgAV with a cross-validated AUC of 0.86 (95% confidence interval 0.75–0.94). The panel’s performance indicates potential clinical utility for stratifying renal involvement, pending further validation.
The study demonstrates that a single LC-MS assay performed on a very small plasma volume can capture an IgAV-associated IgA1 hinge O-glycoform signature that is present in acute disease and normalizes in remission, along with a distinct set of glycoforms associated specifically with renal involvement. Analytical reproducibility was acceptable (median CV 6%), and selected glycoforms and a composite panel showed strong discrimination for disease state and nephritis.
The authors note that prospective longitudinal studies are required to determine whether the renal-associated panel can predict subsequent development of nephritis, as this cross-sectional work identifies candidate signatures but does not establish predictive validity. Data from the present study are available from the authors on reasonable request, and ethical approvals and consents were reported as obtained for the work.
Overall, these results support further evaluation of IgA1 hinge-region O-glycoforms as biomarkers for disease activity and renal involvement in pediatric IgAV, with the next steps being longitudinal validation and assessment of clinical utility in risk stratification.